ARQT — Expiration of Patent US9907788 for ZORYVE
Jun 7, 2037, 12:00:00 AM UTC
Summary
The patent US9907788 for ZORYVE, assigned to Arcutis Biotherapeutics Inc, is set to expire on June 7, 2037. ZORYVE is a topical treatment that leverages a formulation to improve the bioavailability and efficacy of roflumilast, a phosphodiesterase 4 inhibitor used to treat certain dermatological conditions. The patent's expiration could allow for increased market competition and potential generic versions of the drug, impacting Arcutis's financial landscape.
Company
ARCUTIS BIOTHERAPEUTICS INC (ARQT)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.arcutis.comSimilar Events
Patent Expiration for ZORYVE (US11129818)
Patent US11129818 for ZORYVE, a topical formulation of roflumilast, will expire on August 25, 2037, potentially impacting the product's exclusivity and market position. The patent covers improved delivery methods and a longer plasma half-life for the therapeutic, which is significant for treatment effectiveness. As patent expiration may lead to generic competition, this could materially affect Arcutis Biotherapeutics Inc.'s revenues from ZORYVE once exclusivity ends.
Patent ExpirationPatent US11707454 Expiration for ZORYVE
The expiration of patent US11707454 for ZORYVE, a topical treatment containing roflumilast, is set for December 3, 2041. This patent covers the use of roflumilast for treating fungal infections and conditions such as seborrheic dermatitis and various types of tinea infections. The expiration may allow for increased competition in the antifungal market, potentially impacting Arcutis Biotherapeutics Inc's market position as alternatives become available.
patentPatent US12042487 Expiry Related to ZORYVE
The patent US12042487 related to ZORYVE, a PDE-4 inhibitor drug developed by Arcutis Biotherapeutics Inc, expires today. This patent covers a method to improve the pharmacokinetics of a PDE-4 inhibitor formulation, specifically aimed at reducing gastrointestinal side effects and enhancing patient compliance by managing the spike in Cmax through the combination of the inhibitor with phosphate ester surfactants.
Patent ExpiryExpiration of Patent US9763953 for ZUNVEYL
Neurodyn Life Sciences Inc and Alpha Cognition Inc will see the expiration of Patent US9763953 for ZUNVEYL on December 1, 2026. ZUNVEYL is a product that enhances neuronal cholinergic receptor sensitivity and acts as a cholinesterase inhibitor, potentially functioning as a neuroprotective agent. The patent protects compounds with improved blood-brain barrier permeability, derived from amaryllidaceae alkaloids. The expiration may impact market competition and pricing for ZUNVEYL, increasing access to generic alternatives.
patent expiryExpiration of Patent USRE44638 for ZYDELIG
The patent USRE44638 for ZYDELIG, a drug developed by Gilead Sciences Inc, is set to expire on August 5, 2025. This patent covers a class of substituted quinazolinone compounds which are pivotal in treating diseases associated with PI3Kδ activity, including various hematopoietic cancers and bone-resorption disorders. The expiration of this patent may lead to increased competition and potential revenue impact for Gilead, as generic versions of ZYDELIG may enter the market.
Patent ExpirationExpiration of Patent US9949994 for VEKLURY
Patent US9949994 for VEKLURY, a treatment for Filoviridae virus infections including Ebola and Marburg viruses, assigned to Gilead Sciences Inc, is set to expire on October 29, 2035. This expiration could open the market to generic versions, potentially impacting Gilead's revenues significantly as competition increases in the antiviral space.
Patent ExpirationExpiration of Patent US11844858 related to RYZUMVI
The patent US11844858 related to the product RYZUMVI, which involves aqueous ophthalmic solutions of phentolamine for enhancing visual performance, is set to expire on January 31, 2034. This expiration may significantly impact the product's market exclusivity, potentially leading to increased competition in the ophthalmic solutions market. The patent is assigned to Opus Genetics Inc and FAMYGEN LIFE SCIENCES INC.
Patent ExpirationExpiration of Patent US9492449 related to ZYDELIG
The patent US9492449 related to ZYDELIG, a drug developed for the treatment of hematological malignancies and inflammatory diseases, is set to expire on March 11, 2030. This patent covers a novel therapeutic strategy that includes the administration of a specific compound along with additional therapeutic agents. The expiration of this patent may open the market to generic competition, potentially affecting Gilead Sciences, Inc.'s revenue from this product.
Patent ExpirationExpiry of Patent US11884696 for ZURZUVAE
The patent US11884696 for ZURZUVAE, a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid owned by Sage Therapeutics Inc in conjunction with Biogen Inc, is set to expire on August 23, 2037. This patent is critical as it covers the formulation and usage methods of ZURZUVAE, a product aimed at addressing various central nervous system disorders. The expiration could potentially allow generics to enter the market, impacting the financial landscape for both companies.
Patent Expiry